The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

May 3, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this.

You Might Also Like
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis

CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where it is known as Remsima. An advisory committee to the U.S. Food and Drug Administration endorsed it, and the FDA approved the treatment in April. But until now, data on the effect of CT-P13 on mucosal healing were lacking.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To investigate, Dr. Tamas Molnar of University of Szeged in Hungary and colleagues studied 63 UC patients (mean age 30, mean disease duration 5.7 years) who received CT-P13 induction therapy at three IBD clinics in Hungary and one in the Czech Republic. Reasons for starting CT-P13 included acute, severe flare up and chronic, refractory activity.

CT-P13 induction consisted of 5 mg/kg given as an intravenous infusion at Weeks 0, 2 and 6 followed by a maintenance regimen of 5 mg/kg every eight weeks, except for one Czech patient with acute severe disease who received an induction dose of 10 mg/kg.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At baseline, the mean value of total Mayo score was 9.2, with mean endoscopic subscore (eMayo) of 2.7 points at the beginning of the CT-P13 therapy.

At Week 14, the mean value of total Mayo score dropped to 3.4, with eMayo of 1.1. Both scores decreased significantly in responders at Week 14 compared with baseline (p<0.001 and p<0.001)

The cumulative clinical response rate was 82.5%. Steroids could be tapered and stopped in 60% of the patients on systemic corticosteroids at entry.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 14, sigmoidoscopy showed mucosal healing in 38 patients (60.3%), the authors report. Thirty patients (47.6%) had steroid-free mucosal healing. Complete mucosal healing (eMayo of 0) was achieved in 17 (27%) patients. Trough levels of CT-P13 correlated with mucosal healing.

“Infliximab biosimilar CT-P13 represents a promising treatment option for patients with UC not only regarding clinical activity, but also in achieving mucosal healing,” the authors conclude in their paper, online on April 21 in the Journal of Crohn’s and Colitis.

In a related paper in the journal, online on April 19, Dr. Lisa Smits from Radboud University Medical Centre and colleagues report short-term clinical outcomes following a switch from brand name infliximab to CT-P13 in a “real-life” cohort of 83 patients with inflammatory bowel disease.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, infliximab, infliximab-dyyb, monoclonal antibody, ulcerative colitis

You Might Also Like:
  • IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results
  • Switch to Biosimilar Infliximab for IBD Slashes Drug Costs
  • Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.